Biorez Awarded Four New Patents Related to Its Proprietary BioBrace™ Technology
The US Patent Office issued Biorez four key patents over the past three months
OCTOBER 04, 2021
Biorez Inc., a New Haven start-up advancing tendon and ligament healing, announced today that four key utility patents were issued by the United States Patent and Trademark Office between July and September 2021.
The four new patents relate to Biorez’s proprietary BioBrace Implant, which is a biocomposite soft tissue scaffold intended to reinforce soft tissue repair, and act as a biologic scaffold to promote healing.
The BioBrace Implant was cleared by the US Food and Drug Administration in April (K203267) and is indicated “for the reinforcement of soft tissue where weakness exists.”
Unlike traditional implant materials that are either synthetic or biologic in origin, BioBrace is a composite of both. The novel implant’s architecture features a highly porous type I collagen matrix reinforced with bioresorbable PLLA microfilaments. The unique design of the BioBrace enables the mechanical reinforcement of soft tissue repairs, with a bio-inductive scaffold to promote healing.
These recent patent issuances provide protection for the Biorez BioBrace implant and its use in surgery into 2040, and expand Biorez’s patent portfolio to 8 issued US patents, and 16 outside the US. Additional US and foreign patent applications are pending.
“The recently issued 532, 102, 776, and 622 patents are further evidence that Biorez has category-defining innovation with our BioBrace technology,” commented Kevin Rocco, Founder & CEO. “These new patents add to our exceptional year that includes the US FDA regulatory clearance, winning the ACE new technology award at the AOSSM-AANA Annual meeting, and the recent momentum in our limited commercial release.”
Recently Issue Biorez Patents:
Uniformly Titled: Composite scaffold for the repair, reconstruction, and regeneration of soft tissues
US Patent Number: 11,058,532 (Granted 7/13/2021)
US Patent Number: 11,065,102 (Granted 7/20/2021)
US Patent Number: 11,096,776 (Granted 8/24/2021)
US Patent Number: 11,116,622 (Granted 9/14/2021)
Biorez Appoints Jeff Grebner as Director of Clinical AffairsNOVEMBER 01, 2021
Biorez™ Raises $3.5 Million to Close Out $7 Million in Seed FinancingSEPTEMBER 09, 2020
Biorez Hosts Grand Opening Celebration at District in New HavenDECEMBER 19, 2018